Clinical trials
Recurrent Ovarian Cancer clinical trials
Below are recruiting recurrent ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 233 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05467891RecruitingPhase 2
Ribociclib plus hormone therapy for recurrent breast cancer
This trial tests whether adding ribociclib (a targeted pill) to hormone therapy can control breast cancer that has come back in the breast area or nearby lymph nodes/chest wall. It targets hormone-receptor–positive and HER2-negative tumors to help slow disease after local treatment.
Birmingham, AlabamaAges 18 years+ - NCT06188520RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors in women
This trial tests a new drug, AZD8421, alone or with other treatments, for women with advanced solid tumors that have not responded to prior therapies. It aims to find a safe dose and see if it can help shrink or control the cancer.
St Louis, MissouriAges 18 years+ - NCT04823897RecruitingPhase 1
Testing CCI-001 alone and with chemo for recurrent solid tumors
This early study tests whether CCI-001 can be given safely and may help shrink or control recurrent or metastatic (advanced) solid cancers. It checks the right dose first, then studies CCI-001 with standard chemotherapy in certain cancer types.
Edmonton, AlbertaAges 18 years+ - NCT05797168RecruitingPhase 1/Phase 2
Early study drug for advanced solid tumors, alone or with another drug
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
Duarte, CaliforniaAges 18–130 - NCT06777082Recruiting
Study of RPL8 protein in ovarian cancer
This study looks at a protein called RPL8 in a specific type of ovarian cancer called high-grade serous ovarian carcinoma. It may help researchers understand the disease better and find new ways to treat it.
Bologna, BOAges 18 years+ - NCT07303387RecruitingPhase 2
Valemetostat for solid tumors with SWI/SNF gene changes
This trial tests a new drug, valemetostat, for solid tumors that have specific genetic changes (like loss of SMARCB1, SMARCA4, or ARID1A). It is for people whose cancer has continued to grow despite other treatments. The study will see if valemetostat can help shrink or slow tumors.
Villejuif, Val de MarneAges 18 years+ - NCT05128825RecruitingPhase 2
Test drug azenosertib for platinum-resistant ovarian cancer
This Phase 2 trial tests azenosertib to treat platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. It looks for whether the drug can shrink tumors and improve outcomes in people whose cancer has returned after platinum chemotherapy.
Mobile, AlabamaAges 18 years+ - NCT06303505RecruitingPhase 1/Phase 2
Study of TUB-040 for ovarian and lung cancer
This study tests a new drug called TUB-040 that targets a protein (NaPi2b) found on some ovarian and lung cancer cells. It is for people whose cancer has stopped responding to standard treatments and who have not had certain lung problems in the past.
Birmingham, AlabamaAges 18 years+ - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT05559879RecruitingPhase 1/Phase 2
Cabozantinib and dostarlimab for recurrent gynecologic carcinosarcoma
This trial tests the combination of cabozantinib and dostarlimab to treat recurrent (coming back) gynecologic carcinosarcoma, after standard chemotherapy has already been tried. It aims to shrink tumors and improve outcomes by targeting cancer pathways.
Birmingham, AlabamaAges 18 years+ - NCT02543710RecruitingPhase 4
Biomarker-guided treatment for endometrial cancer
This study uses a tumor “biomarker” test to guide treatment in people with endometrial cancer (and sometimes epithelial ovarian cancer). It tests whether tailoring weekly chemotherapy (paclitaxel) based on biomarker levels can help patients, especially when the cancer has come back or is advanced.
NijmegenAges 18–95 - NCT05401162Recruiting
Chemo with your own stem cells for ovarian cancer
This study looks at giving chemotherapy with an added support step using your own collected stem cells. It may help people with recurrent or metastatic ovarian cancer by supporting bone marrow recovery while treatment continues.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT04486352RecruitingPhase 1/Phase 2
Targeted therapy trial for recurrent or persistent endometrial cancer
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
Duarte, CaliforniaAges 18 years+ - NCT06504147RecruitingPhase 2
Radspherin for ovarian cancer with peritoneal spread
This trial tests a radioactive treatment called Radspherin given during surgery for advanced ovarian cancer that has spread to the lining of the abdomen. It is for people whose tumors are HR proficient (a specific genetic type) and who have already had chemotherapy before surgery.
Tampa, FloridaAges 18 years+ - NCT05983107RecruitingPhase 2
Chidamide/Everolimus for advanced breast cancer
This trial tests a combination of two drugs, chidamide and everolimus, for people with advanced HR+/HER2- breast cancer. It aims to see if the combination works for tumors with or without a PIK3CA gene mutation. You may be able to join if you've had previous treatment with CDK4/6 inhibitors and up to two prior chemotherapies.
Beijing, Beijing MunicipalityAges 18–75 - NCT04518501RecruitingPhase 1/Phase 2
Testing fuzuloparib with arsenic and platinum for ovarian cancer
This early-phase study tests a combination of three medicines to treat ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum chemotherapy, especially when tumors have a BRCA1 or BRCA2 mutation. The goal is to see if this treatment can help control cancer that is hard to treat.
Zhejiang, HangzhouAges 18–70 - NCT04644289RecruitingPhase 2
Olaparib plus durvalumab for early testing in ovarian cancer
This study tests whether olaparib and durvalumab given around the time of diagnosis can help people with advanced ovarian cancer. It also strongly focuses on collecting tumor and blood samples to better understand who may benefit.
Mannheim, Baden-WurttembergAges 18 years+ - NCT04752826RecruitingPhase 1/Phase 2
Testing BI-1808 plus Keytruda for advanced cancers
This trial tests a new cancer medicine (BI-1808) either alone or together with Keytruda (pembrolizumab) in people with advanced cancers. It may help by strengthening the immune system’s attack on cancer, especially if standard treatments are no longer working or aren’t suitable.
Duarte, CaliforniaAges 18 years+ - NCT05172310RecruitingPhase 1
PET scan study using a new tracer for solid tumors
This trial tests a special PET/CT scan using a new tracer (68Ga-FAPI) to help show tumors in the pancreas, bile ducts, stomach, or certain ovarian cancers. It may help doctors better see where cancer is in preparation for surgery or biopsy.
StockholmAges 19 years+ - NCT06730347RecruitingPhase 2
Study of lorigerlimab for advanced ovarian and other cancers
This trial tests a new drug, lorigerlimab, for people with certain types of ovarian cancer or related cancers that have come back or not responded to treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06844136Recruiting
ChemoINTEL test study for ovarian cancer
This study is testing a new lab test (called ChemoINTEL) that looks at how your cancer cells respond to chemotherapy drugs used for ovarian cancer. The goal is to see if the test can predict how well the treatment will work for you.
Liverpool, MerseysideAges 18 years+ - NCT06971744RecruitingPhase 2
Study of autophagy maintenance for ovarian cancer
This trial tests whether a combination of medications (hydroxychloroquine, everolimus, and others) can help keep ovarian cancer from coming back after successful platinum chemotherapy plus Avastin. It is for people whose cancer responded well to their most recent chemo and who can continue Avastin maintenance.
Charleston, South CarolinaAges 18 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+
Hear when a new Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent ovarian cancer?
- Yes. Clin2 currently lists 233 recruiting recurrent ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.